Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study

被引：0
|
作者：
Elizabeth Poplin
John Roberts
Marybeth Tombs
Steven Grant
Eric Rubin
机构：
[1] Virginia Commonwealth University,The Massey Cancer Center of the Medical College of Virginia
[2] University of Medicine and Dentistry of New Jersey,The Cancer Institute of New Jersey
来源：
Investigational New Drugs | 1999年 / 17卷
关键词：
gemcitabine; fluorouracil; Phase I study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Gemcitabine is a chemotherapy agent with efficacy in the treatment of lung, pancreas, bladder and breast cancer. It inhibits DNA synthesis by interfering with cytidine triphosphate production and also inhibits the activity of ribonucleotide reductase. Gemcitabine may potentiate fluorouracil's inhibition of thymidylate synthase. This inhibition would be expected to be sequence dependent, occurring only if gemcitabine were administered following fluorouracil (5FU).
引用
收藏
页码：57 / 61
页数：4
相关论文
共 50 条
  • [1] Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
    Poplin, E
    Roberts, J
    Tombs, M
    Grant, S
    Rubin, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 57 - 62
  • [2] A phase I study of 5-fluorouracil, leucovorin and levamisole
    Cleary, JF
    Arzoomanian, R
    Alberti, D
    Feierabend, C
    Storer, B
    Witt, P
    Carbone, P
    Wilding, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) : 300 - 306
  • [3] A phase I study of 5-fluorouracil, leucovorin and levamisole
    J. F. Cleary
    Rhoda Arzoomanian
    Donna Alberti
    Chris Feierabend
    Barry Storer
    Pauline Witt
    P. P. Carbone
    George Wilding
    Cancer Chemotherapy and Pharmacology, 1997, 39 : 300 - 306
  • [4] A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
    Goldberg, RM
    Kaufmann, SH
    Atherton, P
    Sloan, JA
    Adjei, AA
    Pitot, HC
    Alberts, SR
    Rubin, J
    Miller, LL
    Erlichman, C
    ANNALS OF ONCOLOGY, 2002, 13 (10) : 1674 - 1680
  • [5] A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin
    Mulcahy, MF
    Loehrer, PJ
    Meropol, NJ
    Rademaker, AW
    Benson, AB
    ONCOLOGY, 2005, 68 (4-6) : 479 - 484
  • [6] Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer
    Marantz, A
    Jovtis, S
    Almira, E
    Balbiani, L
    Castilla, JL
    Fein, L
    Lewi, D
    Pasccon, G
    Pinckevicius, R
    Uranga, G
    Abal, M
    Muiño, M
    Reale, M
    Agusto, S
    Lastiri, F
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 44 - 49
  • [7] A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors
    Jordan D. Berlin
    Dona B. Alberti
    Rhoda Z. Arzoomanian
    Chris A. Feierabend
    Kris J. Simon
    Kim A. Binger
    Rebecca M. Marnocha
    George Wilding
    Investigational New Drugs, 1998, 16 : 325 - 330
  • [8] A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and or metastatic solid tumors
    Berlin, JD
    Alberti, DB
    Arzoomanian, RZ
    Feierabend, CA
    Simon, KJ
    Binger, KA
    Marnocha, RM
    Wilding, G
    INVESTIGATIONAL NEW DRUGS, 1999, 16 (04) : 325 - 330
  • [9] A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Morgan-Meadows, S
    Mulkerin, D
    Berlin, JD
    Kim, K
    Bailey, H
    Saphner, T
    Jumonville, A
    Hansen, R
    Ahuja, H
    McFarland, T
    Thomas, JP
    ONCOLOGY, 2005, 69 (02) : 130 - 134
  • [10] A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies
    Blanke, CD
    Stipanov, M
    Morrow, J
    Rothenberg, M
    Chinery, R
    Shyr, Y
    Coffey, R
    Johnson, DH
    Leach, SD
    Beauchamp, RD
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (01) : 21 - 27
12345